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Introduction
Rheumatoid arthritis (RA) is a chronic inﬂ ammatory 
joint disease characterized by destruction of periarticular 
bone and cartilage and soft-tissue damage, leading to 
impaired joint function [1]. Bone erosion, periarticular 
osteopenia and systemic bone loss, are central features of 
RA [2]. In a recent cross-sectional study we found that 
RA patients had thinner cortices at the shafts of the tibia, 
radius and metacarpal bone, and that the outer diameter 
of the metacarpal bone was increased. Disease severity, 
measured by the extent of erosions and the cumulative 
dose of glucocorticoids (GCs), correlated negatively with 
shaft cortical thickness [3]. However, despite increased 
outer circumference and thinner cortical shaft, the calcu-
lated load-bearing capacity (strength strain index) of long 
bone shafts was not impaired in RA patients and adap-
tation to muscular strength remained unchanged [4].
In the last years, several case studies have linked RA 
with increased risk of bone shaft fractures at the meta-
tarsal, tibial and femoral bones [5-7]. Since these frac-
tures occur without previous trauma, and are not at 
typical locations for osteoporosis-associated fractures, 
they are called insuﬃ  ciency or atypical fractures. Th e 
reasons for these fractures are not yet known, but 
associated factors are estrogen deﬁ ciency, RA, diabetes, 
GC therapy and treatment with anti-resorptive drugs, 
such as bisphosphonates (BPs). In a recent report of sum-
marized clinical data on cases with shaft fractures 
associated with BP, the task force of the American Society 
for Bone Mineral Research [6] found that patients with 
atypical fractures of the femur had a higher number of 
comorbid conditions such as RA (odds ratio = 16.5) and 
underwent therapy with GC (odds ratio = 5.2) [8].
Findings of a potential association of BP with insuﬃ   ci-
ency fractures are in strong contrast to the actual therapy 
concept and impede the clinician’s decision-making in 
treating RA patients on GCs with BP therapy. Hence, 
there is a need to elucidate the eﬀ ect of RA, BP and GC 
(and their combination) on long-term adaptation of bone 
geometry and bone mineral density.
Physiology of adaptation of bone geometry
Bone adapts its shape in response to prevailing loads by 
bone modeling and remodeling at the outer and inner 
envelopes of the cortical shaft. During bone modeling 
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Bone mass, bone geometry and its changes are based 
on trabecular and cortical bone remodeling. Whereas 
the eff ects of estrogen loss, rheumatoid arthritis (RA), 
glucocorticoid (GC) and bisphosphonate (BP) on 
trabecular bone remodeling have been well described, 
the eff ects of these conditions on the cortical bone 
geometry are less known. The present review will 
report current knowledge on the eff ects of RA, GC 
and BP on cortical bone geometry and its clinical 
relevance. Estrogen defi ciency, RA and systemic GC 
lead to enhanced endosteal bone resorption. While in 
estrogen defi ciency and under GC therapy endosteal 
resorption is insuffi  ciently compensated by periosteal 
apposition, RA is associated with some periosteal bone 
apposition resulting in a maintained load-bearing 
capacity and stiff ness. In contrast, BP treatment leads 
to fi lling of endosteal bone cavities at the epiphysis; 
however, periosteal apposition at the bone shaft 
seems to be suppressed. In summary, estrogen loss, 
RA and GC show similar eff ects on endosteal bone 
remodeling with an increase in bone resorption, 
whereas their eff ect on periosteal bone remodeling 
may diff er. Despite over 50 years of GC therapy and 
over 25 years of PB therapy, there is still need for better 
understanding of the skeletal eff ects of these drugs as 
well as of infl ammatory disease such as RA on cortical 
bone remodeling.
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(construction, growth) bone is deposited at the periosteal 
surface without prior resorption on the endosteal surface, 
leading to an increase in cortical diameter (Figure 1a) [9]. 
During bone remodeling (reconstruction, lifetime adap-
tation to load and age), osteoclasts resorb a small volume 
of bone at a distinct location at the inner site of the cortex 
adjacent to the marrow (Figure  1b) [10]. If periosteal 
appo sition increases (as an adaptive response) to com-
pensate for the loss of strength (caused by endosteal bone 
loss), there will be no loss in bone strength (Figure  1c) 
[11-13]. Alternatively, if periosteal apposition is impaired, 
endosteal resorption will produce cortical thinning and 
loss of bone mass and strength, predisposing to fractures.
Various factors inﬂ uence adaptation of bone geometry. 
Th ese factors include the menopause, GC therapy and 
treat ment with anti-resorptive drugs, as well as diseases 
such as RA, hyperparathyroidism, diabetes mellitus, hypo-
phosphatasia and vitamin D deﬁ ciency and mechanical 
factors such as weight. In the following paragraphs, 
current knowledge on the main factors causing bone loss 
and potentially leading to fractures in patients with RA 
will be summarized and resulting research questions 
highlighted.
Menopause
Estrogen loss during the menopause is the most common 
cause of fractures in older people. Trabecular bone loss 
occurs years before the menopause; at the onset of 
estrogen decline, a phase of rapid bone loss starts, leading 
to loss of an approximate mean of 10% of bone at the 
spine and about 5% at the hip over a period of 5  years 
[14,15]. Th is phase is characterized by bone resorption, 
leading to trabecular thinning and perforation, resulting 
in a loss of connectivity [16]. Th is initial acute phase  – 
the high-turnover phase  – is followed by a long-lasting 
period of slower bone loss where the dominant micro-
architecture change is trabecular thinning and increased 
cortical porosity [17].
On a cellular level, the high-turnover phase is caused 
by an increased activity of osteoclasts, driven by the 
increased production of receptor activator of NF-κB 
ligand [18-20]. Th e second phase is caused by impaired 
osteoblastic activity due to increased osteoblast death 
and decreased function [21]. Estrogen therapy blunts 
bone resorption and stimulates bone formation. Th e 
dominant eﬀ ect of estrogen is the inhibition of osteoclast 
diﬀ erentiation and activation, and, to a lesser extent, 
impairment of apoptosis of the osteoblasts [19,20,22]. 
Studies on bone geometry and strength of the one-third 
distal radius in perimenopausal and postmenopausal 
women showed an accelerated endosteal resorption and 
decreased periosteal apposition at the radius shaft. Th is 
endosteal resorption during the postmenopausal years 
leads to cortical thinning  – and because the outward 
apposition of bone is minimal, the cortical cross-
sectional area and bending strength decrease (Figure 2a) 
[23].
Th inning of the cortical shaft thickness of the radius 
and tibia is associated with an increased fracture risk 
[24]. In estrogen-treated women, loss of bone strength 
was partially prevented [24] and the risk of vertebral and 
hip fracture incidence in postmenopausal women 
declined [25]. In summary, estrogen deﬁ ciency leads to 
thinning and loss of bony trabeculae as well as increased 
endosteal resorption and impaired periosteal bone 
apposition, resulting in a net loss of bone with diminished 
strength to compression and bending.
Rheumatoid arthritis
RA is a chronic inﬂ ammatory joint disease characterized 
by destruction of periarticular bone and cartilage and 
soft-tissue damage, leading to impaired joint function [1]. 
Th e general consensus is that the pathogenic process of 
bone loss in RA patients is due to the abundance of 
osteoclasts [26]. Bone erosion, periarticular osteopenia 
and systemic bone loss are central features of RA [2]. 
Chronic inﬂ ammatory diseases such as RA cause skeletal 
breakdown and enhance the risk of nontraumatic 
fractures [27,28]. Approximately 25% of patients with 
early RA show an osteopenic bone mineral density at the 
spine or hip before the onset of therapy, and 10% have 
osteoporosis [29-32]. A large case–control study based 
on the British General Practice Research Database has 
shown that RA doubles the risk of hip and vertebral 
fractures, supporting the concept that the eﬀ ect of RA is 
independent and additive to GC [33].
With a newly established protocol using peripheral 
quantitative computed tomography (QCT) we investi-
gated the diﬀ erences in volumetric bone mineral density 
(BMD) and bone geometry at the metacarpal bone, tibia 
and radius in 50 female RA patients and compared it with 
100 healthy female controls [3]. We found that RA 
patients had signiﬁ cantly lower trabecular volumetric 
BMD at the distal epiphyses of the radius (–19%), tibia 
(–14%) and metacarpal bone (–12%). At the shafts of 
these bones RA patients had thinner cortices (–7% to 
–16%), and at the metacarpal shaft the outer diameter 
was increased by 5% (Figure  2b). Th e extent of bone 
erosions and the cumulative dose of GCs correlated 
negatively with trabecular and total volumetric BMD as 
well as with shaft cortical thickness [3]. In a subsequent 
study with 64 RA patients and 128 healthy controls, we 
assessed factors associated with diﬀ erences in bone geo-
metry between RA patients and healthy controls. Based 
on linear models with explanatory variables (muscle 
cross-sectional area, age, RA status and sex), we found 
that patients with RA showed a greater age-related 
decrease in cortical thickness with a concomitant increase 
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in outer bone circumference consistent with an enhanced 
aging pattern [4].
Th ese observations suggest that the biological changes 
of endosteal resorption and periosteal bone apposition 
found in healthy populations [11,23,34] are accelerated in 
patients with RA. Possible explanations for this process 
may be inﬂ ammation-driven endosteal resorption, which 
was also found in human juvenile idiopathic arthritis 
[35], experimentally induced inﬂ ammatory knee arthritis 
or adjuvant-induced arthritis [36-38]. Similarly, inhibi-
tion of bone resorption by the anti-receptor activator of 
NF-κB ligand antibody denosumab prevented metacarpal 
shaft bone loss in patients with RA [39]. Periosteal bone 
formation has been found in human studies [35] and in 
animal studies [36-38], with one of these studies 
observing that periosteal bone formation occurred after 
the endosteal resorption, when inﬂ ammation had already 
subsided [38]. Th is observation suggests that periosteal 
bone formation may be a compensatory mechanism to 
restore bone strength. In other words, the calculated 
load-bearing capacity of RA patients was not impaired 
and adaptation to muscular strength remained un-
changed [4].
In summary, RA is associated with an increased endo-
steal bone resorption and compensatory periosteal bone 
formation of the aﬀ ected shafts leading to a change in 
geometry with maintained strength. Longitudinal data 
for the eﬀ ects of inﬂ ammation on bone geometry and 
volumetric BMD in patients with RA have not yet been 
published.
Glucocorticoids
GC use, quantiﬁ ed either by daily or cumulative dosage, 
is strongly related to an increased fracture risk [40,41]. 
Prednisone equivalent >5  mg daily is associated with 
vertebral fractures in postmenopausal women within the 
ﬁ rst 6  months of treatment [42]. Th e relative risk for 
fractures in GC users in a general practice research 
database is 2.86 (95% conﬁ dence interval = 2.31 to 3.16) 
for the spine and 2.01 (95% conﬁ dence interval = 1.47 to 
2.29) for the hip compared with subjects not using GCs 
[42]. Th e areal BMD at the lumbar spine and hip showed 
an up to 12% increased bone loss in GC users compared 
with in nonusers of similar age and sex [42]. A meta-
analysis of the relationship between areal BMD changes 
and fractures showed that low areal BMD was associated 
with a relative risk of 1.48 for vertebral fractures and 1.41 
for hip fractures [43]. Further, it has been shown that 
fractures occurred at a younger age in male GC users 
compared with nonusers at comparable areal BMD [44]. 
Th is ﬁ nding indicates that GCs not only lead to decreased 
areal BMD, but fractures occur at an even higher rate 
than that expected based on areal BMD. One can 
therefore speculate that there is not only a loss in bone 
mass but also in bone quality in GC users. Th e eﬀ ects of 
GC on bone cells include early and quick induction of 
osteoclastogenesis leading to in creased bone resorption 
as well as apoptosis of osteo blasts and osteocyts [45].
Histomorphometric analyses showed trabecular thin-
ning and reduced osteoid thickness, a marker for osteo-
blastic activity in GC users [46,47]. At the iliac crest, 
cortical porosity and Haversian canal density were higher 
in patients treated with GCs [48]. Using QCT of the 
spine, rapid decline of vertebral trabecular volumetric 
BMD was found upon GC treatment with subsequent 
recovery following discontinuation [49]. Th inning of the 
cortical shell at the distal radius was found by peripheral 
QCT [50,51] and at the proximal femur by QCT [52]. 
Consistent with these results, GC administration to 
ovariectomized sheep showed that the cortical width and 
cortical bone area were reduced by 7 to 8% and the 
marrow area increased by 8% in GC-treated animals 
compared with controls (Figure 2a) [53]. Trabecular bone 
formation in the GC-treated animals decreased by 68% 
Figure 1. Adaptation of bone geometry. (a) Cross-section of long bone with marrow cavity (purple) and cortical bone (yellow), bordered by 
endosteal surface to the marrow and periosteal envelope at the outside. (b) Endosteal resorption (dotted area) leads to porosity of cortical bone 
and eventually to the expansion of the marrow cross-sectional area (CSA). (c) Compensatory periosteal bone apposition (area between dashed and 
solid line) results in an increase of total bone CSA. Solid lines, present bone envelopes; dashed lines, past bone envelopes.
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after 2 months and by 90% after 4 months. Th e apparent 
trabecular BMD and compressive stiﬀ ness were reduced 
by 34% and 55%, respectively. Th e results are consistent 
with a substantially reduced bone formation in the cortical 
and trabecular bone and reduced cortical width due to 
increased endosteal resorption. Impaired cortical bone 
remodeling together with increased cortical porosity bears 
the potential for increased fracture risk at appendicular 
bone sites such as the femur and tibia [48,53].
In summary, BMD and bone quality are reduced upon 
GC treatment due to increased endosteal resorption, 
cortical porosity and impaired periosteal apposition. 
Longitudinal data on bone shaft geometry changes in 
GC-treated patients, however, are as yet absent.
Bisphosphonates
BP therapy is the strategy of choice for prevention and 
treatment of bone loss and fractures associated with 
osteoporosis. Current clinical practice treats patients on 
high-dose long-term GC therapy with BP to prevent 
bone loss. BP therapy has been shown to reduce the 
relative risk for new vertebral and hip fractures in 
postmenopausal women by 70% and 50%, respectively, 
over 3 years [54]. Indications for treatment with BPs are a 
quantitative estimate of the 10-year probability of a major 
osteoporotic fracture (clinical spine, hip, forearm or 
shoulder) exceeding 15 to 30% [55-57], inadequate 
vertebral fracture or GC therapy depending on the risk 
category [58].
BPs accumulate in the bone’s hydroxyapatite mineral 
phase, particularly at sites of active resorption [59,60] – 
where the nitrogen-containing BPs enter osteoclasts and 
reduce resorption by initiating early osteoclast death 
[61]. Recent retro spective studies and case reports 
suggest that long-term BP therapy may result in the 
suppression of bone turn over and confer a predisposition 
to increased bone fragility, with an increased risk of 
atypical fractures [62]. Th e number of atypical fractures 
is low – corresponding to an incidence of subtrochanteric 
fractures of 3 per 10,000 person-years – compared with 
the overall incidence of hip fractures (103 per 10,000 
person-years) [63]. Nevertheless, long-term BP use is 
more likely and the duration of BP use longer in patients 
with sub trochanteric and femoral shaft fractures 
compared with patients with typical osteoporotic hip 
fracture [63,64]. Hip fracture incidence declined by 12.8% 
from 1996 to 2007, since BPs were approved, whereas the 
number of subtrochanteric and femoral shaft fractures 
remained stable or even increased in the same period 
[65]. Th is coincidence made the US Food and Drug 
Administration issue an alert with a warning about the 
‘possible risk of rare atypical femur fractures associated 
with BP treatment in osteoporosis patients’ [66].
A causal relationship between BP use and atypical 
femur fractures has not been established, but preclinical 
data evaluating the eﬀ ects of BPs lend biologic plausibility 
to a potential association with long-term BP use. Of 
special interest was the ﬁ nding that patients with femoral 
shaft fractures had a higher number of comorbid 
conditions  – for example, diabetes mellitus, RA (odds 
ratio  = 16.5) and concomitant use of additional anti-
resorptive agent (such as estrogen, raloxifene or calci-
tonin) or systemic GCs (odds ratio  = 5.2)  – than those 
with typical hip fractures [8]. Th is association is striking 
since guidelines suggest treating patients with RA 
undergoing GC treat ment with BPs, either preventa tive 
Figure 2. Bone shaft geometry adaptation to eff ects of estrogen defi ciency, glucocorticoid therapy, rheumatoid arthritis and 
bisphosphonate. (a) Estrogen defi ciency or usage of systemic glucocorticoids leads to enhanced oste oclastogenesis and thus endosteal 
resorption and cortical porosity. However, bone formation in these conditions is inhibited, resulting in a decreased periosteal bone apposition 
that insuffi  ciently compensates for the endosteal resorption. Solid lines, present bone envelopes; dashed lines, past bone envelopes. (b) Under 
infl ammatory conditions such as rheumatoid arthritis (RA) endosteal bone resorption is accelerated, leading to an increase of marrow cross-
sectional area (CSA). Periosteal bone apposition seems to compensate the endosteal bone loss and leads to an increase in total and cortical shaft 
CSA, resulting in a maintained estimated compression and bending strength. (c) Preliminary data in RA patients indicate that bisphosphonate 
may inhibit periosteal bone apposition and does not always stop endosteal bone resorption. In these cases, the endosteal resorption cannot be 
compensated and the cortical thinning predisposes to fractures of long bone shaft.
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to alleviate GC-induced osteoporosis or as therapy of 
already established osteoporosis [58]. In a recent longi-
tudinal study using high-resolution com puted tomo-
graphy to measure the eﬀ ect of alendronate treatment in 
postmenopausal women with low BMD, changes in 
trabecular and endosteal compartments at the epiphyses 
of tibia and radius were found [67]. Particularly at the 
weight-bearing tibia, a ﬁ lling of endosteal bone cavities 
was found with a concomitant decrease in the medullary 
area [67]. At the tibia shaft, however, increased medullary 
area with unaltered periosteal circumference was seen in 
postmenopausal RA patients treated with alendronate 
[68] (Figure 2c).
In summary, the positive eﬀ ects of BP therapy in 
reducing fracture risk are undoubted; in patients with 
comorbid conditions such as RA and GC use, however, 
BPs seem to be associated with atypical femoral fractures, 
for which the reason is not yet known. Th e recent reports 
of the potential association of BPs with atypical femur 
shaft fractures and the recommendations to treat RA 
patients on GCs with BP therapy are in stark contrast to 
the prevailing advice and therefore impede the clinician’s 
decision-making in treating a large proportion of RA 
patients. Further research is needed to address these 
questions.
Conclusion
Current knowledge about the adaptation of bone shaft 
geometry to eﬀ ects of estrogen deﬁ ciency, RA and 
systemic GC therapy suggests an enhanced endosteal 
bone resorption. While in estrogen deﬁ ciency and under 
GC therapy this endosteal resorption is insuﬃ  ciently 
compensated by periosteal apposition (Figure 2a), in the 
RA it seems to be compensated by increased periosteal 
bone apposition (Figure  2b) resulting in a maintained 
load-bearing capacity and stiﬀ ness. BP therapy results in 
ﬁ lling of endosteal bone cavities and hence reduction of 
the endosteal diameter at the epiphysis. However, 
periosteal apposition upon BP treatment in patients with 
osteoporosis has not yet been seen (Figure 2c). More so, 
studies elucidating the eﬀ ect of BP treatment on the bone 
geometry of patients with RA are missing. Further, the 
eﬀ ects of concomitant use of GCs and BPs on the bone 
shaft’s inner and outer bone envelope are unexplored. 
Th ere is a need for answering these questions, and studies 
that further clarify the eﬀ ect of GCs and BPs (and their 
combination) on bone geometry and fragility will shed 
some light on these points.
Rheumatology key messages
• Estrogen loss, RA and GC show increased endosteal 
resorption of bone shaft.
• Periosteal bone remodeling of the bone shaft may be 
increased under inﬂ ammatory conditions.
• Studies are needed to elucidate the eﬀ ect of BP on 
periosteal apposition under inﬂ ammatory conditions.
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